• Users Online: 29812
  • Home
  • Print this page
  • Email this page

    Article Cited by others

SYMPOSIUM

Bevacizumab: Off-label use in ophthalmology

Grisanti Salvatore, Ziemssen Focke

Year : 2007| Volume: 55| Issue : 6 | Page no: 417-420

   This article has been cited by
 
1 Next generation therapeutics for retinal neurodegenerative diseases
Matthew B. Appell, Jahnavi Pejavar, Ashwin Pasupathy, Sri Vishnu Kiran Rompicharla, Saed Abbasi, Kiersten Malmberg, Patricia Kolodziejski, Laura M. Ensign
Journal of Controlled Release. 2024; 367: 708
[Pubmed]  [Google Scholar] [DOI]
2 LC/MS Assessment of Glycoform Clearance of a Biotherapeutic mAb in Rabbit Ocular Tissues
Shiyu Dong, Linzhi Chen, Achim Sauer, Lars Dittus
Journal of Pharmaceutical Sciences. 2023;
[Pubmed]  [Google Scholar] [DOI]
3 Targeting angiogenesis in oncology, ophthalmology and beyond
Yihai Cao, Robert Langer, Napoleone Ferrara
Nature Reviews Drug Discovery. 2023;
[Pubmed]  [Google Scholar] [DOI]
4 A comparison between the effects of two liposome-encapsulated bevacizumab formulations on ocular neovascularization inhibition
Maryam Malakouti–Nejad, Daniela Monti, Susi Burgalassi, Hassan Bardania, Elahe Elahi, Dina Morshedi
Colloids and Surfaces B: Biointerfaces. 2023; : 113708
[Pubmed]  [Google Scholar] [DOI]
5 Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
Debdulal Chakraborty, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Saptorshi Majumdar, Ranabir Bhattacharya, Ritobroto Maitra
Clinical Ophthalmology. 2023; Volume 17: 1067
[Pubmed]  [Google Scholar] [DOI]
6 Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Abraham Hang, Samuel Feldman, Aana P. Amin, Jorge A. Rivas Ochoa, Susanna S. Park
Pharmaceuticals. 2023; 16(8): 1140
[Pubmed]  [Google Scholar] [DOI]
7 Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration
Semra Ozdemir, Eric Finkelstein, Jia Jia Lee, Issac Horng Khit Too, Kelvin Yi Chong Teo, Anna Chen Sim Tan, Tien Yin Wong, Gemmy Chui Ming Cheung, Marie-Helene Errera
PLOS ONE. 2022; 17(8): e0272301
[Pubmed]  [Google Scholar] [DOI]
8 The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection
Nasser A Fugara, Zaineh A Shawareb, Nancy K Rakkad, Manar L Barhoum, Bana A Shawareb, Myrna M Al-Madani, Mousa V Al-Madani
Cureus. 2022;
[Pubmed]  [Google Scholar] [DOI]
9 Faricimab in the Treatment Landscape for Retinal Diseases: A Review
Anna K Wu, David D Chong, Rishi P Singh
US Ophthalmic Review. 2022; 16(2): 92
[Pubmed]  [Google Scholar] [DOI]
10 Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
Azka Ali, Ankit A. Shah, Lauren J. Jeang, Kyle S. Fallgatter, Thomas J. George, David L. DeRemer
Cancer Treatment Reviews. 2022; 105: 102376
[Pubmed]  [Google Scholar] [DOI]
11 Challenges and strategies for the delivery of biologics to the cornea
M. Wels, D. Roels, K. Raemdonck, S.C. De Smedt, F. Sauvage
Journal of Controlled Release. 2021; 333: 560
[Pubmed]  [Google Scholar] [DOI]
12 Mapping of drug-related problems among older adults conciliating medical and pharmaceutical approaches
Marie-Laure Laroche, Thi Hong Van Ngo, Caroline Sirois, Amélie Daveluy, Michel Guillaumin, Marie-Blanche Valnet-Rabier, Muriel Grau, Barbara Roux, Louis Merle
European Geriatric Medicine. 2021; 12(3): 485
[Pubmed]  [Google Scholar] [DOI]
13 Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis
Justus G. Garweg, Christin Gerhardt
Graefe's Archive for Clinical and Experimental Ophthalmology. 2021; 259(8): 2181
[Pubmed]  [Google Scholar] [DOI]
14 Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats
Paulina Jakubiak, Rubén Alvarez-Sánchez, Matthias Fueth, Olaf Broders, Hubert Kettenberger, Kay Stubenrauch, Antonello Caruso
Molecular Pharmaceutics. 2021; 18(6): 2208
[Pubmed]  [Google Scholar] [DOI]
15 Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
Shashikant Sharma, Vishali Gupta, Aniruddha Maiti, Sribhargava Natesh, Sandeep Saxena, Vivek Dave, Vimal Parmar, Raju Sampangi, Hemanth Murthy, Sandhya Dharwadkar, Naresh Kumar Yadav, Shrinivas Joshi, Rahul Mayor, Dhanashree Ratra, Soumyava Basu, Neha Goel, Alok Chaturvedi, Ronak Patel, Vinu Jose
International Journal of Retina and Vitreous. 2021; 7(1)
[Pubmed]  [Google Scholar] [DOI]
16 Hydrogel Biomaterials for Application in Ocular Drug Delivery
Courtney R. Lynch, Pierre P. D. Kondiah, Yahya E. Choonara, Lisa C. du Toit, Naseer Ally, Viness Pillay
Frontiers in Bioengineering and Biotechnology. 2020; 8
[Pubmed]  [Google Scholar] [DOI]
17 Cell-based approaches towards treating age-related macular degeneration
Alireza Baradaran-Rafii, Masoumeh Sarvari, Sepideh Alavi-Moghadam, Moloud Payab, Parisa Goodarzi, Hamid Reza Aghayan, Bagher Larijani, Mostafa Rezaei-Tavirani, Mahmood Biglar, Babak Arjmand
Cell and Tissue Banking. 2020; 21(3): 339
[Pubmed]  [Google Scholar] [DOI]
18 Bevacizumab for eye diseases – Legal, regulatory, and ethical overview
Vinu Jose, Swetha Radhakrishna, Parag Pipalava, Inderjeet Singh
Indian Journal of Pharmacology. 2019; 51(6): 377
[Pubmed]  [Google Scholar] [DOI]
19 ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION IN THE ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ERA
Emily K. Tam, Pamela Golchet, Madeline Yung, Francis C. DeCroos, Marc Spirn, Lydia Lehmann-Clarke, Aude Ambresin, Irena Tsui
Retina. 2018; 38(2): 292
[Pubmed]  [Google Scholar] [DOI]
20 Effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve implantation: a randomized control trial
Arezoo Miraftabi, Naveed Nilforushan, Mina Darghahi, Sayyed Amirpooya Alemzadeh, Mohammad Parsamanesh, Maryam Yadgari
Clinical & Experimental Ophthalmology. 2018; 46(7): 750
[Pubmed]  [Google Scholar] [DOI]
21 Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina
Irene Bravo-Osuna, Vanessa Andrés-Guerrero, Alicia Arranz-Romera, Sergio Esteban-Pérez, Irene T. Molina-Martínez, Rocío Herrero-Vanrell
Advanced Drug Delivery Reviews. 2018; 126: 127
[Pubmed]  [Google Scholar] [DOI]
22 Changing vision: a review of pharmacogenetic studies for treatment response in age-related macular degeneration patients
Janan Arslan, Paul N Baird
Pharmacogenomics. 2018; 19(5): 435
[Pubmed]  [Google Scholar] [DOI]
23 Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF
Natàlia Vilà, Jacqueline Coblentz, Carlos Moreira-Neto, Vasco Bravo-Filho, Pablo Zoroquiain, Miguel N. Burnier Jr.
Ophthalmic Research. 2017; 57(1): 48
[Pubmed]  [Google Scholar] [DOI]
24 Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy
K Ghasemi Falavarjani,M Hashemi,M Modarres,A Hadavand Khani
Eye. 2014;
[Pubmed]  [Google Scholar] [DOI]
25 Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration
Ciro Costagliola,Luca Agnifili,Barbara Arcidiacono,Sarah Duse,Vincenzo Fasanella,Rodolfo Mastropasqua,Marco Verolino,Francesco Semeraro
Expert Opinion on Biological Therapy. 2012; 12(10): 1299
[Pubmed]  [Google Scholar] [DOI]
26 Reduced occurrence of programmed cell death and gliosis in the retinas of juvenile rabbits after short-term treatment with intravitreous bevacizumab
Maria Alice Fusco, André Luís Freire Portes, Silvana Allodi, Haroldo Vieira de Moraes Junior, Mário Luiz Ribeiro Monteiro, Nádia Campos de Oliveira Miguel
Clinics. 2012; 67(1): 61
[Pubmed]  [Google Scholar] [DOI]
27 Perioperative use of bevacizumab in vitrectomy for proliferative diabetic retinopathy: A literature review
Falavarjani, K.G., Modarres, M.
Iranian Journal of Ophthalmology. 2010; 22(2): 5-12
[Pubmed]  [Google Scholar]
28 Short-term response of macular oedema to intravitreal bevacizumab
Welch, D.E., Elmariah, H., Peden, M.C., Adams, S.G., Ratnakaram, R., Kaushal, S.
British Journal of Ophthalmology. 2009; 93(8): 1033-1036
[Pubmed]  [Google Scholar]
29 Bevacizumab for ocular neovascular diseases: A systematic review
Andriolo, R.B., Puga, M.E., Beifort Jr., R., Atallah, Á.N.
Sao Paulo Medical Journal. 2009; 127(2): 84-91
[Pubmed]  [Google Scholar]

 

Read this article